Limited applicability and implementation of the international oncology treatments guidelines in low- and middle-income countries, an example from the Mediterranean area borders.

Breast cancer Cancer du col utérin Cancer du nasopharynx Cancer du sein Cervix cancer Guidelines Low- and middle-income countries Nasopharyngeal cancer Pays à faibles et moyens revenus Radiotherapy Radiothérapie Recommandations Stereotactic radiotherapy Stéréotaxie

Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 02 07 2023
revised: 09 07 2023
accepted: 10 07 2023
medline: 12 9 2023
pubmed: 8 8 2023
entrez: 7 8 2023
Statut: ppublish

Résumé

The quality of cancer care in the modern era is based on a precise diagnosis and personalized therapy according to patients and their disease based on validated guidelines with a high level of evidence. During cancer patients' management, the objective is first to make an accurate diagnosis and then offer the best treatment, validated beforehand in a multidisciplinary board meeting, with the best benefit/risk ratio. In the context of many low- and middle-income countries, the limited available means do not allow an adequate offer, resulting in non-optimal patients' care. In addition, in many low- and middle-income countries, priority can be given to other types of disease than cancer, which may considerably reduce allocation of specific resources to cancer care. Thus, the limited availability of systemic therapy, radiotherapy machines, brachytherapy and technological development may come up against another difficulty, that of geographical distribution of the means in the countries or a lack of expertise due to insufficient training programs. For all these reasons, the implementation of the guidelines established in Western countries could be impossible for many low- and middle-income countries which, moreover, have to face a completely different epidemiology of cancers compared to developed countries. In this work, we will discuss through a few examples of common cancers on both borders of the Mediterranean area, the applicability of the guidelines and the limits of their implementation for optimal cancer care.

Identifiants

pubmed: 37550156
pii: S1278-3218(23)00147-6
doi: 10.1016/j.canrad.2023.07.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

666-675

Informations de copyright

Copyright © 2023 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Y Belkacemi (Y)

Department of Radiation Oncology and Henri-Mondor Breast Center, centre hospitalier universitaire Henri-Mondor, AP-HP, université Paris-Est Créteil, Créteil, France; Inserm U955, i-Biot Team, IMRB, university of Paris-Est Crétil, Créteil, France. Electronic address: yazid.belkacemi@aphp.fr.

M-C Biston (MC)

Centre Léon-Bérard and Creatis, CNRS UMR 5225, Inserm U1044, Insa-Lyon, université Lyon 1, Villeurbanne, France.

N Benchekroun (N)

Department of Radiation Oncology, centre Mohamed-VI, université de Casablanca, Casablanca, Morocco.

A Benider (A)

Department of Radiation Oncology, centre Mohamed-VI, université de Casablanca, Casablanca, Morocco.

C Chargari (C)

Department of Radiation Oncology, groupe hospitalier Pitié-Salpêtrière, AP-HP, Sorbonne Université Paris VI, Paris, France.

K Debbi (K)

Department of Radiation Oncology and Henri-Mondor Breast Center, centre hospitalier universitaire Henri-Mondor, AP-HP, université Paris-Est Créteil, Créteil, France; Inserm U955, i-Biot Team, IMRB, university of Paris-Est Crétil, Créteil, France.

M Doré (M)

Department of Radiation Oncology, Institute de cancérologie de l'Ouest (ICO) centre René-Gauducheau, Saint-Herblain, France.

H El Kacimi (H)

Department of Radiation Oncology, Institut d'oncologie de Rabat, Rabat, Morocco.

I Flandin (I)

Department of Radiation Oncology, centre hospitalier universitaire de Grenoble, Grenoble, France.

I Lalya (I)

Department of Radiation Oncology, hôpital militaire Mohamed-V, Rabat, Morocco.

H Samlali (H)

Department of Radiation Oncology, clinique d'oncologie le Littoral, Casablanca, Morocco.

N Sellal (N)

Department of Radiation Oncology, hôpital universitaire Mohmed-VI, université Abdelmalek-Essadi, Tanger, Morocco.

S Supiot (S)

Department of Radiation Oncology, Institute de cancérologie de l'Ouest (ICO) centre René-Gauducheau, Saint-Herblain, France; Université de Nantes, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH